Coagulation Factor III

Coagulation Factor III

Coagulation Factor III 詳細

Molecule Name
Tissue factor
分子の別称
Coagulation Factor III,Tissue Factor,TF,F3,CD142
Drug Development Progress
治験薬の数7
市販薬剤の数1
研究&開発段階Approved
ターゲットの別称
Coagulation Factor III (Thromboplastin, Tissue Factor),Thromboplastin,Coagulation Factor III, Tissue Factor,TFA,F3,TF,CD142 Antigen,CD142,Coagulation Factor III,Tissue Factor
バックグランド
Full-length tissue factor (TF) is a transmembrane receptor and cofactor for factor (F)VII/FVIIa. In addition to full-length TF, an alternative spliced (as) form of TF can be generated that lacks the transmembrane domain and is released fromcells. In contrast to TF, asTF has low procoagulant activity because it lacks the transmembrane domain. Tissue factor is expressed by cells around blood vessels, such as adventitial fibroblasts, and body surfaces, such as epithelial cells, and plays a critical role in hemostasis. TF also contributes to various forms of thrombosis. Many cancers, particularly adenocarcinomas, express high levels of TF. A high level of tumor TF expression is associated with poor prognosis in many types of cancers, including breast, prostate, colorectal, and pancreatic cancer.

Coagulation Factor III 製品リスト

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
AnpocoginAB-201Phase 3 ClinicalDendreon Uk Ltd
Coronavirus Disease 2019 (COVID-19)
詳細
XNW-28012XNW-28012; XNW28012Phase 3 ClinicalShanghai Cigna Biotech Pharmaceutical Co Ltd
Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Uterine Cervical Neoplasms
詳細
MRG-004AMRG004APhase 3 ClinicalShanghai Miracogen Inc
Pancreatic Neoplasms; Solid tumours
詳細
XB-002XB-002; ICON-2Phase 1 ClinicalIconic Therapeutics Inc
Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Urogenital Neoplasms; Uterine Cervical Neoplasms
詳細
XB-371XB-371; XB371Phase 1 ClinicalCatalent Inc, Exelixis Inc
Neoplasms; Solid tumours
詳細
STRO-004STRO-004Phase 1 ClinicalSutro Biopharma Inc
Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uterine Cervical Neoplasms
詳細
AMT-754ADCE-T02; AMT-754Phase 1 ClinicalMultitude Therapeutics Inc
Solid tumours
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
Tisotumab vedotinTF-011-MMAEApprovedGenmab A/SHuMax-TF, TIVDAKUnited StatesUterine Cervical NeoplasmsSeagen Inc2021-09-20
Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms
詳細